Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Antiobesity agent from Neurogen/Pfizer advances to multiple-dose trials

Feb. 6, 1997

Impotence Rx expected to enter phase II this year

Feb. 5, 1997

FDA panel to review Carticel service

Feb. 5, 1997

GelMed receives patent coverage for new use of polymers

Feb. 4, 1997

Novel diabetes treatments reported by Shaman

Feb. 4, 1997

Pfizer claims glycogen phosphorylase inhibitors

Feb. 4, 1997

Successful completion of phase I trial of aerosolized osteoporosis product

Feb. 3, 1997

Inhale/Lilly collaborate on pulmonary delivery of osteoporosis Rx

Feb. 3, 1997

Hypoglycemic/hypolipidemic agents from Sumitomo Metal

Feb. 3, 1997

Japanese researchers describe compounds for lipoprotein disorders

Feb. 3, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.